Lisa Baust
22Patents
13h-index
3Co-inventors
70Inventor score
Filing activity: Aug 15, 2003 → Jan 27, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8216583B2 | Formulation of human antibodies for treating TNF-α associated disorders | Emerging Cross-Sectional Technologies | 113 | Active |
| US8916157B2 | Formulation of human antibodies for treating TNF-α associated disorders | Emerging Cross-Sectional Technologies | 75 | Active |
| US9114166B2 | Formulation of human antibodies for treating TNF-α associated disorders | Emerging Cross-Sectional Technologies | 60 | Active |
| US8802100B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 57 | Active |
| US8802101B2 | Formulation of human antibodies for treating TNF-α associated disorders | Emerging Cross-Sectional Technologies | 29 | Active |
| US9272041B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 25 | Active |
| US8916158B2 | Formulation of human antibodies for treating TNF-α associated disorders | Emerging Cross-Sectional Technologies | 24 | Active |
| US8940305B2 | Formulation of human antibodies for treating TNF-α associated disorders | Emerging Cross-Sectional Technologies | 21 | Active |
| US8795670B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 21 | Active |
| US9738714B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 21 | Active |
| US8932591B2 | Formulation of human antibodies for treating TNF-α associated disorders | Emerging Cross-Sectional Technologies | 21 | Active |
| US8802102B2 | Formulation of human antibodies for treating TNF-α associated disorders | Emerging Cross-Sectional Technologies | 20 | Active |
| US8911741B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 19 | Active |
| US9220781B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 13 | Active |
| US9289497B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 12 | Active |
| US9295725B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 12 | Active |
| US9272042B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 12 | Active |
| US9302011B2 | Formulation of human antibodies for treating TNF-α associated disorders | Emerging Cross-Sectional Technologies | 12 | Active |
| US9327032B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 12 | Active |
| US9750808B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 8 | Active |
| US9732152B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 7 | Active |
| US9950066B2 | Formulation of human antibodies for treating TNF-alpha associated disorders | Emerging Cross-Sectional Technologies | 6 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.